title: Lenalidomide-induced regenerative macronodules infarction in a cirrhosis patient.
abstract: Hepatic regenerative macronodules observed in hepatic cirrhosis are sensitive to ischemia. Lenalidomide is a thalidomide analog used for the treatment of myelodysplastic syndromes, with pleiotropic activities including induction of apoptosis, inhibition of angiogenesis and broad immunomodulatory effects. It has been approved by the Food and Drug Administration (FDA) in the United States and by the European Medicines Agency (EMEA) in 2007 for the use in combination with dexamethasone in the treatment of relapsed or refractory multiple myeloma. We report a unique observation, which strongly suggests the role of Lenalidomide in hepatic regenerative macronodules infarction.
authors.affiliation: Service de radiologie, hôpital Saint-Antoine, groupe hospitalier Saint-Antoine, AP-HP, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France. vdangouloffros@yahoo.fr
authors.forename: Volodia
authors.initials: V
authors.lastname: Dangouloff-Ros
authors.forename: Pascale
authors.initials: P
authors.lastname: Cervera
authors.forename: Nicolas
authors.initials: N
authors.lastname: Carbonell
authors.forename: Lionel
authors.initials: L
authors.lastname: Arrivé
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D020518:Focal Nodular Hyperplasia / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007238:Infarction / Q000473:pathology*; D000077269:Lenalidomide; D008099:Liver / Q000098:blood supply*; D008103:Liver Cirrhosis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D013792:Thalidomide; D000077269:Lenalidomide